MAPT and Alzheimer disease: This toxic role for protofibrils/oligomers has been recently underlined by the positive results of the CLARITY‐AD phase 3 clinical trial, showing that lecanemab (a monoclonal antibody selectively targeting large soluble Aβ protofibrils) reduces both cognitive decline and the regional progression of tau‐PET in patients with early AD.24